Picture Kentro Design Corporate and Web Design Berlin 600x60px
Organisation › Details

Oxford BioMedica (Group)

Oxford BioMedica plc (LSE: OXB) is a leading gene and cell therapy Group with an unrivalled portfolio of gene therapy products in development and a platform of exclusive and pioneering technologies with which it designs, develops and manufactures unique gene-based medicines for some of world’s largest pharmaceutical companies. Leveraging its proprietary LentiVector® IP and gene delivery system technology platform and unique tumour antigen (5T4), Oxford BioMedica is advancing its pipeline of six gene therapy products addressing diseases for which there are currently no treatments or that are inadequately treated today, including ocular and central nervous system disorders. OXB Solutions, the Group's industry-leading manufacturing and development business, provides services to collaborators and partners working in gene and cell therapy, including Novartis and Immune Design Corp. In addition, the Group has licenced products and IP to Sanofi, Pfizer, GlaxoSmithKline, MolMed, Sigma-Aldrich, Biogen, Emergent BioSolutions and ImaginAb. Further information is available at *


Please contact us with your proposals. Thank you!
Period Start 1996-01-01 splitoff
  Predecessor University of Oxford
Product Industry gene therapy
Persons Person Dawson, John (Oxford BioMedica 200810– CEO before Cephalon Europe)
  Person 2 Paynter, Stuart (Oxford BioMedica 201708– CFO before De La Rue plc + Shire Pharmaceuticals + Steris)
Region Region Oxford, Oxfordshire
  Country United Kingdom (GB)
  Street Windrush Court
  City OX4 6LT Oxford
  Tel +44-1865-783000
    Address record changed: 2018-07-24
Basic data Employees D: 101 to 500 (2018-12-31)
  Currency GBP
  Annual sales 66,778,000 (revenue, consolidated (2018) 2018-12-31)
  Profit 7,541,000 (2018-12-31)
  Cash 32,244,000 (2018-12-31)
    * Document for �About Section�: Oxford BioMedica plc. (3/7/16). "Press Release: Oxford BioMedica Announces Expanded Collaboration and Licence with Immune Design". Oxford.
Record changed: 2019-03-18


Picture [LSUS] – The Business Web Portal 650x112px

More documents for Oxford BioMedica (Group)

To subscribe to our free, monthly newsletter for the European life sciences, please send an e-mail to and simply fill the subject line with the word »LSE Newsletter«

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]


Picture EBD Group BioPharm America 2019 Boston September 650x65px

» top